Susquehanna International Group, LLP Solid Biosciences Inc. Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.43 - $1.24 $17,647 - $50,890	41,041 Added 212.3%	60,373 $37,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.79 $60,665 - $146,744	-81,980 Reduced 80.92%	19,332 $23,000
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.46 $68,456 - $99,647	-40,507 Reduced 28.56%	101,312 $177,000
Q3 2021 Nov 15, 2021	BUY	$2.38 - $3.77 $279,666 - $443,001	117,507 Added 483.33%	141,819 $339,000
Q2 2021 Aug 11, 2021	SELL	$3.49 - $5.51 $60,460 - $95,455	-17,324 Reduced 41.61%	24,312 $89,000
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $1,621 - $3,237	302 Added 0.73%	41,636 $230,000
Q4 2020 Feb 16, 2021	BUY	$3.08 - $7.79 $54,100 - $136,831	17,565 Added 73.9%	41,334 $313,000
Q3 2020 Nov 16, 2020	SELL	$2.02 - $3.08 $80,244 - $122,353	-39,725 Reduced 62.56%	23,769 $48,000
Q2 2020 Aug 14, 2020	SELL	$2.1 - $3.42 $517,878 - $843,402	-246,609 Reduced 79.52%	63,494 $186,000
Q1 2020 May 15, 2020	SELL	$2.31 - $4.43 $257,278 - $493,395	-111,376 Reduced 26.43%	310,103 $741,000
Q4 2019 Feb 14, 2020	BUY	$2.82 - $12.9 $931,434 - $4.26 Million	330,296 Added 362.23%	421,479 $1.88 Million
Q3 2019 Nov 14, 2019	SELL	$4.33 - $11.64 $74,978 - $201,558	-17,316 Reduced 15.96%	91,183 $943,000
Q2 2019 Aug 16, 2019	BUY	$4.6 - $10.13 $34,109 - $75,113	7,415 Added 7.34%	108,499 $624,000
Q2 2019 Aug 14, 2019	SELL	$4.6 - $10.13 $626,602 - $1.38 Million	-136,218 Reduced 57.4%	101,084 $581,000
Q1 2019 May 15, 2019	BUY	$7.19 - $32.37 $1.71 Million - $7.68 Million	237,302 New	237,302 $2.18 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $36.5M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.